Causaly, a maker of an AI platform for biopharmaceutical drug discovery, raised a $60 million Series B that gives the company "several years" of runway, CEO Yiannis Kiachopoulos tells Axios.
Driving the news: Causaly is this week's second major investment in AI for drug discovery after Nvdia invested $50 million in tech-enabled drug discovery company Recursion on Wednesday.
